Oraya TherapyTM Stereotactic Radiotherapy for Wet AMD
The Oraya Therapy is now available in Germany, Switzerland and the United Kingdom. Additional locations coming soon. For more information, call 0800-690-6495 in the United Kingdom and in Germany call 0800-283-2243.
Full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.
Press Release: First National Health Service hospital in UK and four prestigious hospitals in Germany adopt Oraya Therapy to maintain vision with reduced anti-VEGF injections.
Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics More >
Published ahead of print, Ophthalmology, September 2014. More >
Published ahead of print, RETINA, August 2014. Download >
Published in Expert Reviews of Ophthalmology, 2014. Download >
Published in Ophthalmology, September 2013. Download >
Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment. More >
Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD. More >
Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye. More >